The Great Rotation: Buy This Sector Before It Comes Back in Style

The article argues healthcare insurance stocks are materially beaten down, highlighting UnitedHealth Group’s 50% decline from highs and Oscar Health’s rapid growth to 3.4 million enrolled members. UnitedHealth posted 2025 revenue of $448 billion and net income of $19 billion despite an 88.9% medical loss ratio, while Oscar expects 2026 operating income of $250 million to $450 million as pricing normalizes. The tone is constructive on the sector, but the piece is primarily opinion-driven rather than a fresh catalyst.

Analysis

The setup is less about “cheap healthcare” and more about a cyclical repair in underwriting discipline after a period when rate-setting lagged claims inflation. The first-order beneficiaries are the largest incumbents with the best data, pricing power, and distribution depth; the second-order winner is the broader managed-care ecosystem, because a reset in margin expectations can lift multiple expansion across the group even before earnings recover. That said, the market is still underpricing how long it can take for medical-cost normalization to show up in reported results, which argues for a months-long rather than weeks-long catalyst window.

UNH is the cleaner expression of a recovery because scale and vertical integration let it absorb volatility better than pure-play insurers, but that same integration keeps antitrust overhang alive. The more important second-order effect is that improving Medicare Advantage economics should relieve pressure on provider reimbursement negotiations and PBM margin scrutiny, but it may also invite renewed policy attention if margins rebound too quickly. So the trade is not “buy because everything is fixed”; it is “buy because expectations have been reset below the floor needed for even mediocre execution.”

OSCR is the more reflexive, higher-beta version of the same thesis. The bull case depends on enrollment growth translating into credible loss-ratio improvement, but that is exactly where the consensus is fragile: growth without pricing discipline can compound losses faster than scale benefits arrive. The contrarian angle is that the market may be over-penalizing ACA political noise relative to the actual earnings sensitivity, yet underestimating how quickly a bad claims cycle can erase the perceived technology premium.

Net: this is a tactical-to-intermediate duration longs-only setup in a hated sector, with UNH as the higher-quality recovery and OSCR as the optionality trade. A pair structure makes sense because the fundamental repair thesis is stronger than the regulatory overhang, but idiosyncratic headline risk remains high enough that position sizing should be smaller than normal until 2026 pricing evidence is visible.

Key Decisions for Investors

• Long UNH on any 5-10% pullback over the next 1-3 months; target a 12-18 month recovery to re-rate toward a market multiple if medical loss ratios stabilize, with downside capped by franchise durability but headline risk from regulation.
• Trade OSCR as a high-beta tactical long only if the stock confirms post-enrollment strength; use a smaller starter position and treat it as a 6-9 month earnings-surprise trade, not a core compounder.
• Pair trade: long UNH / short a basket of weaker managed-care names with less scale or worse pricing power over 6-12 months; thesis is that the market will reward underwriting repair and punish laggards that cannot offset claim inflation.
• Buy UNH call spreads 6-12 months out instead of outright equity if you want convexity to margin normalization while limiting exposure to a renewed antitrust headline cycle.
• Avoid chasing OSCR on strong open-interest-driven squeezes; if entered, use defined-risk options or tight stop-losses because the stock can reprice violently on one bad claims print.